The private-credit arm of Guggenheim Investments has employed a novel tool to attract institutional investors to its newest fund as it contends with fierce fundraising competition from other ...

DAVOS, Switzerland (Reuters) - Guggenheim Partners' chief investment officer forecast on Monday that the U.S. Federal Reserve is likely to cut interest rates roughly every quarter in 2025 ...

Guggenheim Strategic Opportunities Fund's earnings haven't fully supported distributions, relying heavily on return of ...

Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

Teradata (NYSE:TDC – Free Report) had its price target trimmed by Guggenheim from $42.00 to $37.00 in a research report sent to investors on Wednesday,Benzinga reports. The brokerage currently has a ...

Guggenheim has outlined four major scenarios ... In other recent news, Piper Sandler, a prominent investment bank, has provided an update on potential catalysts for biotechnology companies up ...

NEW YORK, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Guggenheim Investments today announced that certain closed-end funds have declared their distributions. The table below summarizes the distribution ...

Guggenheim analyst Shahriar Pourreza maintained a Hold rating on Spire (SR – Research Report) today and set a price target of $67.00. The ...

Consult a professional regarding your specific legal or tax matters. Guggenheim Investments is the global asset management and investment advisory division of Guggenheim Partners, LLC ...